Our results indicate that NDUFB8, NDUFA6, COX6C, COX5B, and USMG5 might influence the immune microenvironment of multiple myeloma patients, as well as the response to treatment and prognosis of patients with this disease. This evidence concerns the gene NDUFA6 and plasma cell myeloma.